Rationale for Therapeutic Approaches with Thymosin α 1, Interleukin 2 and Interferon in Combination with Chemotherapy

Cartesio Favalli,Antonio Mastino,Sandro Grelli,Francesca Pica,Guido Rasi,Enrico Garaci

DOI: https://doi.org/10.1007/978-1-4615-3340-5_33

1992-01-01

Abstract:Nowadays a new category of substances defined as “Biological response Modifiers” (BRMs) is currently under careful experimentation in order to ascertain its effectiveness in the stimulation of immune response. Among these various substances, the interferons (IFNs) (Bunn et al., 1986; Jaffe and Herberman, 1988), the interleukin 2 (IL-2) (Rosenberg et al., 1984; Lotze et al.,1985a; Lotze et al., 1985b), and the thymic hormones (THs) (Hooper et al., 1975; Goldstein and Schulof, 1984), are important particularly in the studies on experimental immunotherapy of cancer in animals and in humans. These substances, share the common characteristic of being physiologically involved in the regulation of the ontogenesis and of the activation of different immune cells, and are considered to exert a certain selective action on the immune response. Furthermore they are available in large quantities by biotechnological (IFNs and IL-2) or by chemical synthesis (THs) techniques. Results, however, have not always been positive and sometimes inferior to expectations and indicate that when applied alone, these BRMs display only restricted efficacy. One of the difficulties affecting these results could be that of establishing treatment dosages which must produce simultaneously both biological action and non-toxic effects. Another potential difficulty, particularly for IL-2 and IFNs, is the possibility of tumor cell resistance to cytokines, as recently described (Killion and Fidler, 1990). This resistance could be attributable either to non-responsiveness of host killer cells to the cytokines stimulating action, or to the tumor cells resistance to the cytotoxic activity by stimulated attacker cells.